Brief: Ocuphire Provides Corporate Update And Reiterates Previous Guidance On Clinical Programs

Opus Genetics

25/04/2023 13:51

Ocuphire Pharma Inc  OCUP.O :
    * OCUPHIRE PROVIDES CORPORATE UPDATE AND REITERATES PREVIOUS
GUIDANCE ON CLINICAL PROGRAMS
    * OCUPHIRE PHARMA INC - ORAL APX3330 END OF PHASE 2 MEETING
WITH
FDA ANTICIPATED IN 2023 TO ALIGN ON REGULATORY PATH FOR DIABETIC
RETINOPATHY
    * OCUPHIRE PHARMA INC - PDUFA DATE OF SEPTEMBER 28, 2023 SET
FOR
NYXOL IN ITS FIRST INDICATION, REVERSAL OF
PHARMACOLOGICALLY-INDUCED MYDRIASIS (RM)
    * OCUPHIRE PHARMA INC - PRELIMINARY (UNAUDITED) CASH BALANCE
AS OF
MARCH 31, 2023 OF $39 MILLION IS EXPECTED TO FUND OPERATIONS
INTO 2025

Source text for Eikon:  ID:nGNX3Y1JJ2 
Further company coverage:  OCUP.O